GUILFORD, Conn., Nov. 13 /PRNewswire/ — The Rothberg Institute for Childhood Diseases (TRI), a non-profit research institute devoted to discovering medicines for orphan childhood diseases such as Tuberous Sclerosis Complex (TSC), today announced the release of the first Malaria target to an international community of more than 54,000 users from 93 countries currently running the Drug Design and Optimization Laboratory software (D2OL).
The article contains background information about malaria.
